reports
Absci Reports Business Updates and First Quarter 2024 Financial and Op...
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our internal and partnered programs according to plan," said Sean McC...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
TELA Bio to Announce First Quarter 2024 Financial Results
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Absci to Report Business Updates and First Quarter 2024 Financial and ...
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial a...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and roboti...
Sono-Tek Announces Preliminary Net Sales for Q4 and FY2024 and Provide...
Sono-Tek Announces Preliminary Net Sales for Q4 and FY2024 and Provides Preliminary Sales Guidance for Q1 FY2025 and FY2025 - 12-Month Net Sales Reached ~$19.7 million, Gain of ~31% for FY2024 ended Feb 29, 2024- - Q4 Net Sales Grew ~30% YOY; Backlog Grew ~7% YOY and Remains Strong- - Strong Sales Projected for Q1 FY2025- MILTON, N.Y., April 08, 2024 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced preliminary net sales and backlog for the fourth quarter of fiscal year 2024, ended February 29...
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affai...
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein ...
Sono-Tek Welcomes Dr. Adeniyi Lawal to Board of Directors
Sono-Tek Welcomes Dr. Adeniyi Lawal to Board of Directors - Dr. Lawal has Deep Renewable Energy Expertise in Chemical Energy Conversion Processes - MILTON, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, announced the election of Dr. Adeniyi Lawal to the Company’s Board of Directors effective today. Dr. Lawal is expected to eventually replace Dr. Donald F. Mowbray, the Board member with the most significant technical expertise, who has indicated that he may not stand for reelection and whose current term exp...
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Con...
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on Monday, April 8th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: . About Absci is a data-f...
Sono-Tek to Present at The LD Micro Invitational XIV
Sono-Tek to Present at The LD Micro Invitational XIV Presentation on Tuesday, April 9, 2024, at 8:30 am ET MILTON, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings. Sono-Tek is scheduled to present on Tuesday, April 9, 2024, at 8:30 am ET. Dr. ...
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues an...
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter and $58.5 mil...
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 F...
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results ...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices. LIQUIFIX FIX8 is indicated for minim...
TELA Bio Announces Sale of Distribution Rights for Wound Care Product ...
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX TELA Bio to receive at least $8 million and up to $12 million in total consideration MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the sale of its distribution rights related to NIVIS Fibrillar Collagen Pack to Atlanta-based MiMedx Group, Inc. (“MIMEDX”). As consideration for the sale, MIMEDX will make an initial $5.0 million payment and additional future pa...
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
CLFD CLEARFIELD INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
HWBK HAWTHORN BANCSHARES
FMC FMC CORPORATION
RIGN TRANSOCEAN LTD.
SPWR SUNPOWER CORPORATION
AFT APOLLO SENIOR FLOATING RATE FUND INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
HCC WARRIOR MET COAL INC.
RBB RBB BANCORP
AXR AMREP
FSK FS KKR CAPITAL CORP
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
BSBK BOGOTA FINANCIAL CORP.
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
THRY THRYV HOLDINGS
ABCL ABCELLERA BIOLOGICS
LSEA LANDSEA HOMES CORP (A)
LUMN LUMEN TECHNOLOGIES INC.
SLRC SOLAR CAPITAL LTD.
ONDS ONDAS HOLDINGS
PFX PHENIXFIN CORP
WES WESTERN MIDSTREAM PARTNERS LP
ABSI ABSCI CORP
VPV INVESCO PA VALUE MUNI INC TST
GATO SUNSHINE SILVER MINING AND REFINING CORP
LSXMA LIBERTY SIRIUSXM GROUP
LSXMK BURKE HERBERT FINANCIAL SERVICES CORP
BHRB ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
MDRX INC.
- Jonathan Moreland
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MEG. MEG ENERGY CORP.
EVRI EVERI HOLDINGS INC.
SOY SUNOPTA INC.
CELH CELSIUS HOLDINGS INC.
ATEX ANTERIX INC
ACEL ACCEL ENTERTAINMENT (A)
CMPR CIMPRESS PLC
LSEA LANDSEA HOMES CORP (A)
DFH DREAM FINDERS HOMES
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
NOTV INOTIV INC
LZ LEGALZOOM.COM INC
ABSI ABSCI CORP
HIPO HIPPO HLDGS INC
Moody's announces completion of a periodic review of ratings of Adtale...
Moody's Investors Service (Moody's) has completed a periodic review of the ratings of Adtalem Global Education Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 28 February 2024 in which Moody's reassessed the appropriateness of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.